COVID-19 Management in Pediatrics

Alcindor, Magalie L; Alcindor, Fitz Gerald; Richard, Kristy E.; Ajay, Geetha; Denis, Anne Marie; Dickson, Darlene M.; Lawal, Ekaete; Alcindor, Magaline A; Allen, Deborah H.

doi:10.1016/j.nurpra.2021.02.010

Cited by 3 publications

(2 citation statements)

References 37 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Based on evidence that was available on December 20, 2020, the panel suggested against routine administration of monoclonal antibody therapy (bamlanivimab, or casirivimab and imdevimab) for treatment of COVID-19 in children or adolescents, including those at high risk of progression to hospitalization or severe disease [ 116 ]. At that time, it was expected that the approval of vaccines by the FDA under emergency use authorization for children and adolescents will be a better way to protect those most vulnerable [ 85 , 117 ].…”

Section: Early Research On Treatment Effectsmentioning

confidence: 99%

The COVID-19 pandemic in children and young people during 2020-2021: Learning about clinical presentation, patterns of spread, viral load, diagnosis and treatment

et al. 2021

View full text Add to dashboard Cite

Section: Early Research On Treatment Effectsmentioning

confidence: 99%

The COVID-19 pandemic in children and young people during 2020-2021: Learning about clinical presentation, patterns of spread, viral load, diagnosis and treatment

et al. 2021

View full text Add to dashboard Cite

“…In children, however, COVID-19 infection occurs in less than 12% of all diagnosed cases. Children with preexisting health conditions, such as obesity, may be at a higher risk of clinical decompensation and serious illness [6]. Although rare, when serious complications arise in children, they are diverse and span multiple organ systems.…”

Section: Introductionmentioning

confidence: 99%

The use of monoclonal antibody therapy in pediatric patients with COVID-19: a retrospective case series

et al. 2022

View full text Add to dashboard Cite

Background Monoclonal antibody (MCA) therapies have been utilized under emergency use authorization (EUA) for high-risk pediatric patients with mild to moderate coronavirus disease 2019 (COVID-19) in the outpatient setting since late 2019. The purpose of this study was to describe the use of MCA therapy in pediatric patients in the pediatric emergency department (ED) at a large community hospital. Methods This was a retrospective case series of high-risk pediatric patients 12 to 17 years of age who received MCA therapy in the pediatric ED between December 8, 2020 and June 3, 2021. The primary outcome was to describe the patient characteristics, clinical presentation, and safety profile of the pediatric population that received MCA therapy. The secondary outcome was to describe the incidence of hospitalizations or ED visits up to 28 days following therapy. Results A total of 44 patients were included in the analysis. The median number of days of symptoms was 4 with 41% of patients having symptoms between 0 and 3 days at time of MCA administration. Only one patient experienced a mild adverse event that did not require epinephrine administration. Two patients returned to the ED for reevaluation during the study follow-up period. No patients required admission within 28 days post-therapy. Conclusions The administration of MCA therapy in high-risk pediatric patients in the pediatric ED was well-tolerated with subjective improvement noted in COVID-19 symptoms post-therapy. Further studies are necessary to determine the role MCA therapy may play in reducing morbidity from COVID-19 infection in high-risk pediatric patients.

show abstract

Caracterización de una población pediátrica de escasos recursos que habita por encima de 2500 m. s. n. m., positiva para SARS-COV-2

et al. 2022

View full text Add to dashboard Cite

La infección por el nuevo SARS-COV-2 ha impactado de diversas maneras a toda la sociedad, incluidos los niños. Se describe el comportamiento de esta enfermedad en una población pediátrica de escasos recursos localizada por encima de 2500 m. s. n. m. Este es un trabajo retrospectivo transversal entre marzo y octubre de 2020 en Bogotá involucró niños entre 1 mes y 14 años con rt-pcr positiva para SARS-COV-2. Se estudiaron antecedentes, características sociodemográficas, clínicas, de laborato- rio, radiológicas y evolutivas, agrupando los pacientes según la gravedad y analizando su significancia (p < 0.05). Como resultado, se obtuvieron 416 casos, de los cuales 43.3 % eran asintomáticos, 46.6 % sintomáticos leves, 8.9 % graves y 1.2 % críticos. De los consultantes a urgencias, los menores de 1 año fueron los más frecuentes (56.79 %) y los que más se hospitalizaron (35.8 %). El tiempo entre el inicio de los síntomas y la consulta fue en promedio de 2 días, El diagnóstico más frecuente en los pacientes no hospitalizados fue rinofaringitis (58.97 %), y en los que se hospitalizaron fue bronquiolitis (50 %). La mediana del tiempo de hospitalización de todo el grupo fue de 4 días la cual ser prolongó a 7 días para los que requirieron UcI. Con la hospitalización se asocia, entre otras causas, los índices nutricionales < 2 DE, taquipnea, dificultad respiratoria, hipoxemia, linfopenia (en mayores de 2 años) (p < 0.05), no influyendo el hacinamiento ni el nivel socioeconómico. Después del estudio, se pudo concluir que la enfermedad es, generalmente, mucho más leve en niños que en adultos, diferenciándose de estos tanto en los factores predisponentes, los paraclínicos y en la evolución. Sin embargo, algunas variables demográficas, clínicas y de laboratorio podrían asociarse con una mayor gravedad en este grupo poblacional.

show abstract

COVID-19 Management in Pediatrics

Cited by 3 publications

References 37 publications

The COVID-19 pandemic in children and young people during 2020-2021: Learning about clinical presentation, patterns of spread, viral load, diagnosis and treatment

The COVID-19 pandemic in children and young people during 2020-2021: Learning about clinical presentation, patterns of spread, viral load, diagnosis and treatment

The use of monoclonal antibody therapy in pediatric patients with COVID-19: a retrospective case series

Caracterización de una población pediátrica de escasos recursos que habita por encima de 2500 m. s. n. m., positiva para SARS-COV-2

Contact Info

Product

Resources

About